Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs have been gaining popularity in Saudi Arabia in recent years due to their effectiveness in treating excessive bleeding.
Customer preferences: Patients in Saudi Arabia prefer Anti-Fibrinolytic Drugs due to their ability to prevent blood clots and reduce bleeding during surgical procedures. The drugs are also preferred for their ease of use and relatively low cost compared to other treatments.
Trends in the market: The Anti-Fibrinolytic Drugs market in Saudi Arabia is expected to grow steadily in the coming years due to an increase in the number of surgical procedures being performed in the country. The rise in the number of surgeries can be attributed to the growing population and an increase in chronic diseases such as diabetes and obesity. Additionally, the government’s efforts to improve healthcare infrastructure and increase healthcare spending are expected to further boost the market.
Local special circumstances: The Saudi Arabian government has been investing heavily in the healthcare sector, with the aim of improving the quality of healthcare services and reducing the country’s dependence on foreign healthcare providers. This has led to the establishment of several world-class hospitals and healthcare facilities across the country, which has in turn increased the demand for Anti-Fibrinolytic Drugs.
Underlying macroeconomic factors: The Saudi Arabian economy has been growing steadily in recent years, driven by the government’s efforts to diversify the economy away from oil. The healthcare sector has been identified as a key growth area, and the government has been investing heavily in the sector to support its growth. This has led to an increase in healthcare spending, which has in turn boosted the Anti-Fibrinolytic Drugs market. Additionally, the country’s growing population and rising incidence of chronic diseases are expected to further drive the demand for Anti-Fibrinolytic Drugs in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
